丹麦制药公司诺和诺德（Novo Nordisk A/S）周五报告称，该公司下一代减肥药之一monlunabant在较高剂量时减重效果有限，而且有一定副作用，导致该公司股价周五下跌。

Nissen and colleagues investigated whether treatment with one such CB1 antagonist, rimonabant, could slow the progression of coronary atherosclerosis in obese patients with the metabolic syndrome.

消息面上，诺和诺德在官网发布了药物“monlunabant”2a期临床试验的主要结果。整体来看， 与安慰剂相比，该药物具有显著统计学意义的体重减轻。但在较高剂量的组别中，体重额外减轻的效果有限。

Curioni C and André C (2006) Rimonabant for overweight or obesity. The Cochrane Database of Systematic Reviews, Issue 4, Art. No CD006162.pub2 Rimonabant is the only drug currently under ...

Why Corbus Pharmaceuticals sees Novo Nordisk’s controversial approach to obesity drugs as a ticket to a blockbuster.

The RIO-Diabetes study, which was performed in 159 centers in 11 countries, showed that rimonabant 20 mg once daily can reduce body weight and improve cardiovascular and metabolic risk factors in ...

Shares of Novo Nordisk A/S fell after the Danish drugmaker reported mixed safety data on one of its next-generation ...

The results from the study showed that the patients taking the higher dose of rimonabant lost more weight after one year than those who had taken a placebo. As in the animal studies, rimonabant ...

The Federal Reserve yesterday cut interest rates by 50 basis points, in its first time cutting rates in four years. And how ...

CB1 receptors Skye highlights safety advantages of large-molecule CB1 inhibition compared to small-molecule approach ...

Skye launched its Phase 2 trial of nimacimab in obesity in August 2024. This trial, which is the first to also assess a GLP-1/CB1 inhibitor combination, is expected to report interim weight loss data ...

For instance, in 2008, a weight-loss drug called rimonabant was taken off the market due to its association with an increased ...